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Abstract
Purpose—To describe the prevalence and signs of early and late age-related macular
degeneration (AMD) in an old cohort.
Design—Population based cohort study
Participants—We included 5,272 persons 66 years and older, randomly sampled from the
Reykjavik area.
Methods—Fundus images were taken through dilated pupils using a 45°digital camera and were
graded for drusen size, type, area, increased retinal pigment, retinal pigment epithelial
depigmentation, neovascular lesions and geographic atrophy using the modified Wisconsin Age-
Related Maculopathy Grading System.
Main outcome measure—Age-related macular degenerationin an old cohort.
Results—Mean age of participants was 76 years. The prevalence of early AMD was 12.4% (95%
confidence interval [CI] 11.0–13.9) for those 66–74 year old and 36% (95% CI 30.9–41.1) for
those 85 years and older. The prevalence of exudative AMD was 3.3% (95% CI 2.8–3.8) and for
pure geographic atrophy 2.4% (95% CI 2.0–2.8). The highest prevalence for late AMD was among
those 85 years and older 11.4% (95% CI 8.2–14.5) for exudative AMD and 7.6% (95% CI 4.8–
10.4) for pure geographic atrophy.
Conclusion—Persons 85 years and older have 10-fold higher prevalence of late AMD than those
70–74 years old. The high prevalence of late AMD in the oldest age-group and expected increase
of old people in the western world in coming years call for improved preventive measures and
novel treatments.
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Introduction
Age-related macular degeneration (AMD) is the leading cause of blindness in the world.
1,2,3,4 Data from population-based epidemiological studies have shown considerable
variation in the prevalence of neovascular AMD and geographic atrophy among different
racial/ethnic groups.5,6,7,8 We have in previous studies6,9,10,11, presented results suggesting
that the geographic atrophy may be more common in Iceland than in other white
populations. These estimates were based on rather small numbers in the oldest age-groups.
Because treatment approaches and risk of visual impairment differ, precise prevalence
estimates based on larger numbers of persons over 80 years of age are lacking and needed to
understand the burden of different types of advanced AMD in the very old.12 In the western
world, this age-group is expected greatly to increase in numbers in coming years. The
purpose of this article is to report prevalence of early and late signs of AMD in this large
and relatively old cohort, and to compare the prevalence with age specific estimates from
other populations.
Material and Methods
The Age, Gene/Environment Susceptibility (AGES) Reykjavik Study is a population based
study aimed to investigate genetic and environmental factors contributing to health,
disability and disease in older people, including systemic disease as well as eye disease. The
study design and assessment of the cohort have been described elsewhere.13, 14 In 2002,
when the AGES Reykjavik Study began, 11,549 previously examined cohort members, from
the Icelandic Heart Association's Reykjavik cohort (1967–1996), were still alive according
to the Icelandic Census Database, and 5,764 individuals randomly chosen from the
survivors, were examined for the AGES – Reykjavik Study during 2002–2006.15 The
comprehensive AGES protocol required each participant to complete 3 visits to the Icelandic
Heart Association (IHA) Research Center, within a window of 3–6 months.13 The ocular
component was included as part of the third visit where 5,330 persons participated. As a part
of the assessments at the IHA Research Center a questionnaire was administered, a clinical
examination performed and images were acquired from the retina and brain.14 Transport to
the IHA clinic was provided for those who asked for it, including persons in nursing homes,
care units for the elderly and hospitals. In these latter institutions 251 persons (4.7%) were
bedridden and unwilling or unable to visit the clinic, gave an interview, did however not
have eye examination. The AGES – Reykjavik Study was approved by the Icelandic
National Bioethics Committee (VSN: 00–063), which acts as the Institutional Review Board
for the Icelandic Heart Association, and by the Institutional Review Board for the US
National Institute of Ageing, National Institute of Health.
Fundus Photography
Fundus photography was performed using a standardized protocol that has been described in
detail elsewhere.16,17,18 In brief, after pharmacologic dilation of the pupils, photography
was performed in each eye using a 45° 6.3-megapixel digital nonmydriatic camera (Canon,
Lake Success, NY). Two photographic fields were taken of each eye, the first centered on
the optic disc and the second centered on the fovea. Software was used for image acquisition
and archiving (Eye QSL, Digital Healthcare Inc., Cambridge, United Kingdom).
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Fundus Image Grading
Retinal images were evaluated by the University of Wisconsin Ocular Epidemiology
Reading Center for assessment of AMD in a semiquantitative fashion by a grader masked to
any information about the participant using EyeQ Lite (an image-processing database for
storage, retrieval, and manipulation of digital images), using a standard AMD grading
protocol18, including the modified Wisconsin age-related maculopathy grading system used
in the Multi Ethnic Study of Atherosclerosis.5 Among the AMD features evaluated were
drusen size, type, and area; increased retinal pigment; retinal pigment epithelial
depigmentation; pure geographic atrophy; and signs of exudative macular degeneration
(subretinal hemorrhage, subretinal fibrous scar, retinal pigment epithelial detachment, and/or
serous detachment of the sensory retina or laser or photodynamic treatment for neovascular
AMD). Each image was graded twice (preliminary and detail grades) online using a
modification of the Wisconsin Age-Related Maculopathy Grading scheme.17 Every digitized
image was graded using the full complement of image enhancement tools (e.g.,
magnification, contrast enhancement, lightening, red-free) according to preset protocols.
However, final scoring of an AMD lesion required its appearance on the nonenhanced
image.
If the preliminary and detail gradings agreed (73.2%), the grading was considered final. If
there was disagreement between gradings for a lesion, the image was sent to a third (edit)
grader for reevaluation for that lesion without knowing what the specific disagreement was
(25.9%). The preliminary, detail, and edit gradings were compared again for agreement. If
the third grading agreed with either the preliminary or the detail grading, that grading was
considered final. If a disagreement was present among all 3 graders, the image was
evaluated by the Reading Center co-director (RK), whose grading was used (0.9%). Nine
different graders performed the gradings.
Definitions of Variables
Soft distinct drusen were defined by size (usually between ≥63 and 300μm in diameter) and
appearance (sharp margins and a round nodular appearance with a uniform density [color]
from center to periphery). Soft indistinct drusen were the same size as the soft distinct, but
have indistinct margins and a softer, less solid appearance. Increased retinal pigment appears
as a deposition of granules or clumps of gray or black pigment in or beneath the retina.
Retinal pigment epithelium (RPE) depigmentation is characterized by faint grayish–yellow
or pinkish–yellow areas of varying density and configuration without sharply defined
borders. Early AMD was defined by either the presence of any soft drusen (distinct or
indistinct) and pigmentary abnormalities (either increased retinal pigment or RPE
depigmentation) or the presence of a large soft drusen ≥125 μm in diameter with a large
drusen area (>500 μm-diameter circle) or large (≥125 μm in diameter) soft instinct drusen in
the absence of signs of late AMD. Late AMD was defined by the presence of any of the
following: geographic atrophy or exudative AMD including at least one of the following:
pigment epithelial detachment, subretinal hemorrhage or visible subretinal new vessel, or
subretinal fibrous scar or laser treatment scar for AMD. When two eyes of a participant were
discrepant for the severity of a lesion, the grade assigned for the participant was that of the
more severely involved eye. For example, in assigning the prevalence of soft drusen, if soft
drusen were present in one eye but not in the other eye, the participant was considered to
have soft drusen. When drusen or signs of AMD could not be graded in an eye, the
participant was assigned a score equivalent to that in the other eye.
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Quality Control
Intergrader and intragrader agreements were assessed using the kappa statistic on a random
subset of images of 25 eyes. There were excellent interobserver and intraobserver
agreements among the 9 graders on the 3-level AMD classification (kappa statistic _0.88 to
1.0 and 0.82 to 1.0, respectively) and for exudative AMD (kappa statistic 0.88 to 1.0 for
both). There were substantial interobserver and intraobserver agreements on presence of
large drusen size (kappa statistic 0.76 to 1.0 and 0.71 to 1.0, respectively), soft distinct
drusen (kappa statistic 0.75 to 1.0 and 0.61to 1.0, respectively), increased retinal pigment
(kappa statistic 0.63 to 0.92 and 0.50 to0.85, respectively), and geographic atrophy (kappa
statistic 0.53 to1.0 and 0.52 to1.0). There were moderate interobserver and intraobserver
agreements on the presence of RPE depigmentation (kappa statistic 0.47 to 0.87 and 0.38 to
0.87, respectively).
Statistical analysis
For statistical analysis we used SPSS (version 13.0, 2004, SPSS Inc. Chicago, Illinois,
USA). The prevalence of age-related maculopathy was calculated in 5-year age groups with
95% confidence intervals, using descriptive statistics. Chi-square and logistic regression
analysis were used to compare differences in odds ratio and control for possible interactions
and confounding variables.
Results
Of the 5,330 persons invited for eye examination 5,272 had readable photographs for Age-
related macular degeneration (AMD) in at least one eye (98.9%).
Figure 1 shows the number of participants with readable photographs from at least one eye,
by age-groups and gender. The mean age was 76 years (SD +/− 6, range 66–91 years).
Women represented 58% of the cohort. There were 3,160 participants, 75 years or older and
1,628 persons, 80 years and older who had readable photographs. Figure 2 displays for
comparison the percentage, by sex and birth cohort, of the surviving members of the IHA's
Reykjavik cohort in 2002, the AGES participants in 2004 (the median year of the study), and
residents of comparable age, living in the greater Reykjavik area in 2004.
The frequency of various AMD lesions was highest in the oldest age group (Tables 1–3,
Figure 3). Table 1 presents the age specific prevalence of various AMD lesions which do not
differ significantly by gender, while there was a significant gender difference for phenotypes
reported in tables 2 and 3. Drusen larger than 125μm were found in 18.1% of persons 70–74
year old and in 52.7% of those 85 years and older (table 1) a statistically significant increase
with age (Odds Ratio (OR)=1.12; 95% confidence interval [CI] 1.10–1.13, p<.0001). Soft
distinct drusen were found in 24.3% of those 70–74 years old and 60.5% of those 85 years
and older. Overall age was significantly related to the risk of having soft indistinct drusen
(OR=1.12; 95% CI 1.10–1.13, p<.0001) (table 2) and having soft drusen area larger than
500ȝm in worse eye (OR = 1.14; 95% CI 1.12–1.15, p<.0001)(table 2). After controlling for
age, females had a significantly higher prevalence than males of soft indistinct drusen
(OR=1.18; 95% CI 1.01–1.37, p=0.032) and soft drusen area larger than 500μm (OR=1.22;
95% CI 1.05–1.43, p= 0.012) (table 2). There was no significant gender difference for
pigmentary abnormalities, nor for right and left eyes.
Table 3 shows a steep increase in prevalence of exudative AMD by age, sex and worse eye.
In the age-group 70–74 year old, 1% is affected by exudative AMD, increasing to 11.4%
among those 85 years and older. There is no significant gender difference.
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Table 3 also includes pure geographic atrophy by age, sex and worse eyes excluding persons
with exudative macular degeneration in the contralateral eye or concurrently in the same
eye, both being included in the exudative AMD group only. Here there is an increase from
0.5% for those 70–74 years old to 7.6% for those 85 years and older. If however all persons
with GA in either eye are included irrespective of also having exudative AMD the respective
prevalence for GA is 1.2% for those 70–74 year old and 11.3% for those 85 years and older.
Unilateral exudative AMD was observed in 118 persons (163 eyes), 65 in the right eye, 53
in the left eye and 45 had bilateral AMD. GA was observed in 188 persons, 105 people had
unilateral GA and 83 had GA in both eyes. Of these, 142 persons had pure GA, (89
unilateral and 53 bilateral). The prevalence of exudative AMD and pure GA is presented in
table 3.0.2% of the participants and 1% of those 85 years and older had received laser and/or
photodynamic therapy in at least one eye prior to their AGES Study visit.
Examining the relationships between pigmentary abnormalities and different drusen types
and sizes we find that this relationship is strong and varies little between subtypes. An eye
with increased pigment is significantly more likely to have drusen larger than 125μm (OR =
10.91; 95% CI 9.09–13.10, p<.0001), soft distinct drusen (OR = 9.40; 95% CI 7.78–11.35,
p<.0001), or soft indistinct drusen (OR = 14.57; 95% CI 11.97–17.74, p<.0001). Eyes with
RPE depigmentation are significantly more likely to have drusen larger than 125μm (OR =
11.10; 95% CI 8.81–13.99, p<.0001), to have soft distinct drusen (OR = 7.77; 95% CI 6.14–
9.84, p<.0001), or soft indistinct drusen (OR = 15.76; 95% CI 12.74–19.50, p<.0001). All
these calculations were done controlling for the effects of age and sex. We do not find
similar significant associations between pigmentary abnormalities and drusen area large than
500μm.
Discussion
In this population based study of 5,272 old Caucasian adults, we found a steep age-related
increase in the prevalence of late stages of AMD, including 277 persons with late AMD in at
least one eye. The large size of our study ensured narrow 95% confidence intervals around
the prevalence rates by 5-year age-groups. Our emphasis is on the oldest age-groups where
population based estimates of prevalence of AMD are most limited.12 Comparisons of
estimates of AMD prevalence with other studies are limited because of differences among
studies age-group cut points and methods used to detect and define AMD.
Our data for late AMD for those ≥ 70 years seem higher than those reported in most
population-based studies.7, 19, 20, 21 To our knowledge the only study outside of Iceland,
found to have higher age specific prevalence of late AMD than the present study is a study
of Greenland Inuits. A limitation of the Inuit study is the small numbers in the oldest age-
groups.22 Pooled data from the United States of America (USA) finds GA to be about one
third less prevalent than exudative AMD in the age-group examined23, other European, USA
and Australian studies found exudative AMD twice as common as pure geographic atrophy,
19,20, 24–26 and an Asian Indian study found exudative AMD to be 83% of all late AMD.27
We speculate that Icelanders may be more likely to develop geographic atrophy than
Indians, because they are less pigmented and possibly more vulnerable to age-related retinal
pigment epithelial loss than Indians. The Reykjavik Eye Study (RES) in 1996 had main
emphasis on early AMD and therefore more than two – thirds of the participants were 50–69
years old.6 Older participants were few in particular those 80 years and older. The RES
found the prevalence of late AMD for those 70–79 year old to be 4.8% with wide confidence
margins while the prevalence of the present study for this age-group is 2.9% (95% CI 2.2 –
3.5). In RES there were too few participants 80 years and older for statistical analysis.
Considering late AMD, the proportion of geographic atrophy compared to exudative AMD
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is however higher in the oldest age-group in the present study affecting comparisons with
other studies. In the age-group 75–84 years, exudative AMD outnumbers pure GA by nearly
times 1.3. We use the term pure GA for the endstage of atrophy of RPE with no evidence
ever of exudative or neovascular process. Exudative process like e.g., serous detachment
may however settle down into GA with no residual of exudative AMD and in cross sectional
study be misclassified. In our experience, this is however uncommon in this population. We
do not use the term pure exudative since this category may include cases with (primary) GA
in one eye or even in both eyes, if occurred before seen in this study, as well as exudative
AMD. This so called mixed type of late AMD where GA precedes the exudative AMD was
found in about 15% of persons with late AMD in one of our previous studies.28 In the
present study 2.4% of persons have pure GA and additionally 1.4% have GA where
exudative AMD is also found in the same or in the contra lateral eye totalling 3.8%.
Prevalence of exudative AMD is 3.3% including those with both pure exudative AMD and
some additionally concurrently with primary GA (mixed type). This suggests that the
prevalence may be similar for both the late forms of AMD in this aged population. Less than
0.5% of the participants had received photodynamic and/or laser therapy. Examining the
exudative AMD subphenotypes it seems that at least 2/3rds of those with exudative AMD are
likely to have received anti-vascular endothelial growth factor (anti-VEGF) treatment had it
been available at the time.
Prevalence of drusen ≥125μm by worse eye, sexes combined for persons 70–74 year old and
75–79 year old is 18.1% and 32.5%, respectively in the present study is about third higher
than the rate reported in the European Eye (EUREYE) Study24 and the pooled USA Study23.
Our study also seems to have higher prevalence for drusen ≥125 μm and soft indistinct
drusen than the white participants in the Multi-Ethnic Study of Atherosclerosis (MESA
Study).5 Our prevalence of drusen in this age range may, however, be more similar to the
Proyecto Vision and Eye Research (VER) Study.25 Although women and men of
comparable age appear to develop early or late AMD at about the same rate we found that
women were significantly more likely than men to develop soft indistinct drusen and soft
drusen area >500 μm although for the latter lesions, the numbers are rather low and cautious
interpretation is called for. Significant gender differences were not found for the other
drusen phenotypes. Increased pigmentation (17.5%), decreased pigmentation (8.5%) and any
pigmentary abnormalities (17.5%) for persons 70–79 years seem about twice as high as
those in Hispanics in the Proyecto VER25, the Los Angeles Latino Eye Study7 and the
Rotterdam Study.26 The estimates in the present study are more similar to the findings of the
Beaver Dam Eye Study20 and the Blue Mountains Eye Study19. After correcting for age and
gender eyes with increased pigment have 10.9 fold increased risk of having drusen ≥125
μm, 9.4 fold increased risk of having distinct drusen and 14.6 fold increased risk for having
indistinct drusen and the same numbers for decreased pigmentation are 11.1, 7.8 and 15.8,
respectively. The prevalence of early age-related macular degeneration for those 70–79
years old in our study is 18.3% (95% CI 16.8–19.7) as compared to 8.4% in the Blue
Mountains Eye Study19, 12.8% for the Los Angeles Latino Study7, 29.6% for the Beaver
Dam Eye Study20 and for those 80 years and older the prevalence across the studies are
31.2% (95% CI 28.7–33.6), 14.7%, 27.1%, 39.7%, respectively. When comparing across
different studies, it is important to keep mind differences in study sampling of the oldest old,
in the acquisition of retinal images and classification of graded lesions. Some of the older
studies used stereoscopic 30° films while more recent studies, including ours use digital
imaging, which may contribute, in part, to differences of the estimated prevalence for some
of the phenotypes.
Anti-VEGF treatment currently available for exudative AMD may leave dry scars similar in
appearance to a non-exudative phenotype of AMD and this may make identification of
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phenotypes more specifically of exudative AMD even more difficult to discern in future
population based studies of AMD.
In summary: persons 85 years and older have a 10-fold higher prevalence of late AMD than
those aged 70–74 years. GA is found in approximately half of all those affected with late
AMD, a somewhat higher proportion than in other white populations of comparable age.
Given the frequency of the advanced form of AMD observed in this elderly cohort of
Icelanders, together with an increased life expectancy witnessed around the globe one may
anticipate that the global burden AMD will increase in coming years. An improved
understanding of the factors predictive of the development of specific AMD lesions, will
take on increasing importance when developing new therapeutic strategies and novel
treatment options.
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Figure 1.
Number of persons with readable photographs in at least one eye by age-groups and gender.
Age, Gene/Environment Susceptibility Study - Reykjavik
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Figure 2.
The age distribution, by sex and birth cohort, of members of the original Reykjavik Study
cohort alive in 2002, the Age, Gene/Environment Study (AGES) participants, and of all
residents of comparable age living in the greater Reykjavik area in 2004.
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Figure 3.
Prevalence (%) of early (black column) and late age-related macular degeneration (AMD)
(gray column) by age groups (n=5272).
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